These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

573 related items for PubMed ID: 19826038

  • 1. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.
    Huang X, Gao L, Wang S, Lee CK, Ordentlich P, Liu B.
    Cancer Res; 2009 Nov 01; 69(21):8403-11. PubMed ID: 19826038
    [Abstract] [Full Text] [Related]

  • 2. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
    Huang X, Wang S, Lee CK, Yang X, Liu B.
    Cancer Lett; 2011 Aug 01; 307(1):72-79. PubMed ID: 21497990
    [Abstract] [Full Text] [Related]

  • 3. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
    Pedersen NM, Breen K, Rødland MS, Haslekås C, Stang E, Madshus IH.
    Mol Cancer Res; 2009 Feb 01; 7(2):275-84. PubMed ID: 19208749
    [Abstract] [Full Text] [Related]

  • 4. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
    Wang S, Huang X, Lee CK, Liu B.
    Oncogene; 2010 Jul 22; 29(29):4225-36. PubMed ID: 20498641
    [Abstract] [Full Text] [Related]

  • 5. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells.
    Wang S, Huang J, Lyu H, Lee CK, Tan J, Wang J, Liu B.
    Cell Death Dis; 2013 Mar 21; 4(3):e556. PubMed ID: 23519125
    [Abstract] [Full Text] [Related]

  • 6. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells.
    Daly JM, Jannot CB, Beerli RR, Graus-Porta D, Maurer FG, Hynes NE.
    Cancer Res; 1997 Sep 01; 57(17):3804-11. PubMed ID: 9288791
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.
    Liu B, Ordonez-Ercan D, Fan Z, Huang X, Edgerton SM, Yang X, Thor AD.
    Mol Cancer Res; 2009 Nov 01; 7(11):1882-92. PubMed ID: 19861407
    [Abstract] [Full Text] [Related]

  • 9. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.
    Chen X, Yeung TK, Wang Z.
    Biochem Biophys Res Commun; 2000 Nov 02; 277(3):757-63. PubMed ID: 11062025
    [Abstract] [Full Text] [Related]

  • 10. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide.
    Tan M, Lan KH, Yao J, Lu CH, Sun M, Neal CL, Lu J, Yu D.
    Cancer Res; 2006 Apr 01; 66(7):3764-72. PubMed ID: 16585203
    [Abstract] [Full Text] [Related]

  • 11. 5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2.
    Strasser S, Maier S, Leisser C, Saiko P, Madlener S, Bader Y, Bernhaus A, Gueorguieva M, Richter S, Mader RM, Wesierska-Gadek J, Schott H, Szekeres T, Fritzer-Szekeres M, Krupitza G.
    Differentiation; 2006 Dec 01; 74(9-10):488-98. PubMed ID: 17177846
    [Abstract] [Full Text] [Related]

  • 12. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
    Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, Spector NL.
    Oncogene; 2005 Sep 15; 24(41):6213-21. PubMed ID: 16091755
    [Abstract] [Full Text] [Related]

  • 13. Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells.
    Kim KK, Lee JJ, Yang Y, You KH, Lee JH.
    Carcinogenesis; 2008 Apr 15; 29(4):704-12. PubMed ID: 18258606
    [Abstract] [Full Text] [Related]

  • 14. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes.
    Drummond DC, Marx C, Guo Z, Scott G, Noble C, Wang D, Pallavicini M, Kirpotin DB, Benz CC.
    Clin Cancer Res; 2005 May 01; 11(9):3392-401. PubMed ID: 15867240
    [Abstract] [Full Text] [Related]

  • 15. Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth.
    Zhao YH, Zhou M, Liu H, Ding Y, Khong HT, Yu D, Fodstad O, Tan M.
    Oncogene; 2009 Oct 22; 28(42):3689-701. PubMed ID: 19668225
    [Abstract] [Full Text] [Related]

  • 16. Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.
    Jani JP, Finn RS, Campbell M, Coleman KG, Connell RD, Currier N, Emerson EO, Floyd E, Harriman S, Kath JC, Morris J, Moyer JD, Pustilnik LR, Rafidi K, Ralston S, Rossi AM, Steyn SJ, Wagner L, Winter SM, Bhattacharya SK.
    Cancer Res; 2007 Oct 15; 67(20):9887-93. PubMed ID: 17942920
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
    Wang S, Huang J, Lyu H, Cai B, Yang X, Li F, Tan J, Edgerton SM, Thor AD, Lee CK, Liu B.
    Breast Cancer Res; 2013 Oct 15; 15(5):R101. PubMed ID: 24168763
    [Abstract] [Full Text] [Related]

  • 18. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H, Huang J, Edgerton SM, Thor AD, He Z, Liu B.
    Int J Clin Exp Pathol; 2015 Oct 15; 8(6):6143-56. PubMed ID: 26261492
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.